The Board has recommended dividend of Rs. 2.5/- per share (face value of Re. 1/- each) on the equity shares of the Company for FY 2025-26 subject to the approval of the Shareholders at ....
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals reported mixed FY 2025-26 results. On a consolidated basis, total income rose to Rs 1,74,431 million (up 30% from Rs 1,34,355 million), with PAT growing 30% to Rs 13,619 million and EPS at Rs 48.26. However, standalone financials show a loss of Rs 2,008 million versus profit of Rs 16,104 million last year, driven by Rs 18,008 million in exceptional items. These include antitrust litigation settlements (Rs 6,989 million), inventory provisions for GST 2.0 changes (Rs 4,958 million), and asset impairments (Rs 2,279 million). The Board has recommended a dividend of Rs 2.5 per share (250%) for FY 2025-26, subject to shareholder approval.
The consolidated results show strong operational growth of 30% in revenue and PAT, but the large exceptional charges on standalone basis signal significant one-time legal and inventory-related costs that may continue to impact near-term profitability despite positive underlying business performance.